Clinical Trial Update: Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for INS365 Ophthalmic Solution in keratoconjunctivitis sicca (dry eye) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• INS365 Ophthalmic Solution (INS365)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Keratoconjunctivitis Sicca | Phase 3 | Status: COMPLETED